Pune: Infantry soldier Tariq Aziz (30) is set to return to active duty after undergoing a bilateral lung transplant — the ...

Brinsupri, which Insmed acquired from AstraZeneca nearly a decade ago, is the first treatment for bronchiectasis that’s not ...

A first-in-class reversible dipeptidyl peptidase-1 (DPP-1) inhibitor, brensocatib addresses the underlying inflammatory ...

Liquidia stock shot higher Tuesday after its new drug, Yutrepia, widely beat prescription and patient start expectations.

The diagnosis of chronic obstructive pulmonary disease, or COPD, is improved by incorporating CT lung imaging and respiratory ...

Researchers have found a promising treatment breakthrough for chronic obstructive pulmonary disease (COPD) that avoids many ...

Insmed has received FDA clearance for the first treatment for a chronic lung disease, opening the biotech up to what could be ...

Adding a MET gene inhibitor enhances the effect of combined chemotherapy and immunotherapy in small cell lung cancer (SCLC), ...

Large cohort study finds interstitial lung disease independently increases lung cancer risk across all major subtypes, even ...

The FDA has granted accelerated approval to Hernexeos for the treatment of adults with unresectable or metastatic non-squamous NSCLC.

Net loss for the three months ended June 30, 2025, was $41.6 million or $0.49 per basic and diluted share, compared to a net loss of $28.7 million, or $0.38 per basic and diluted share, for the three ...

The plaintiff is a neurosurgeon at the University of Virginia. He sued the University of Physicians Group alleging that a UVA ...